TruScreen Launches NZD $3 Million Capital Raise to Expand Global Cervical Cancer Screening

TruScreen Group Limited (ASX: TRU), a medical technology company specializing in cervical cancer screening, has announced an NZD $3 million capital raise. The initiative includes a placement to institutional investors and a share purchase plan for existing shareholders, both offering shares at NZ$0.022 with free 12-month options. Proceeds will fund strategic growth across key markets including China, India, Indonesia, and several ASEAN nations. It will also support large-scale public screening programs in Vietnam, Zimbabwe, and Uzbekistan, enhance HPV product distribution in collaboration with Dalton Bioscience, and provide working capital. TruScreen continues to gain international recognition with its inclusion in global health guidelines and WHO-led AI initiatives. The company reported substantial progress in FY2025, including expanded sales in Indonesia and increased sensor usage in China, solidifying its impact on women’s health globally

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com